- Report
- August 2022
United States
From €1766EUR$1,940USD£1,500GBP
- Report
- August 2022
Global
From €719EUR$790USD£611GBP
- Report
- August 2022
Global
From €901EUR$990USD£765GBP
- Report
- August 2021
Global
From €3632EUR$3,990USD£3,084GBP
- Report
- February 2021
Global
From €2694EUR$2,960USD£2,288GBP
- Report
- April 2023
- 26 Pages
Global
€11150EUR$12,250USD£9,470GBP
- Report
- October 2023
- 81 Pages
Global
From €3500EUR$4,119USD£3,077GBP
- Report
- May 2022
- 73 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Report
- April 2022
- 207 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Report
- August 2023
- 266 Pages
Global
From €2275EUR$2,499USD£1,932GBP
€3249EUR$3,570USD£2,760GBP
The Nephropathy Drug market is a subset of the larger Liver and Kidney Disorders Drugs market. It is composed of drugs used to treat nephropathy, a condition that affects the kidneys and can lead to kidney failure. These drugs are used to reduce inflammation, control blood pressure, and reduce the risk of further damage to the kidneys. They can also be used to treat other conditions such as hypertension, diabetes, and lupus.
The Nephropathy Drug market is highly competitive, with many companies offering a variety of treatments. These companies include major pharmaceutical companies such as Pfizer, Merck, and Novartis, as well as smaller companies such as Amgen, AstraZeneca, and Bristol-Myers Squibb. Additionally, there are many generic drug manufacturers that offer lower-cost alternatives to brand-name drugs. Show Less Read more
